Cryo-Cell International (CCEL) vs DaVita (DVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
DaVita (DVA) has outperformed Cryo-Cell International (CCEL) over the past year, gaining 34.9% versus a loss of 11.3%. Over five years, DVA leads with a +57.5% price change compared with -70.3% for CCEL. DaVita is the larger company by market cap ($11.28 billion vs $31.5 million), about 357.8 times the size.
On valuation, DaVita trades at a lower forward P/E (10.3x vs 195.5x for Cryo-Cell International).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCEL | DVA |
|---|---|---|
| Share price | $3.91 | $176.78 |
| Market cap | $31.52M | $11.28B |
| 1-day change | +0.77% | -2.01% |
| YTD return | +13.66% | +55.60% |
| 1-year return | -11.34% | +34.91% |
| 5-year return | -70.27% | +57.54% |
| P/E ratio (TTM) | — | 14.93 |
| Forward P/E | 195.50 | 10.31 |
| EPS (TTM) | $-0.31 | $11.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $13.64B |
| Revenue growth (YoY) | — | +6.46% |
| Net income (latest FY) | — | $746.80M |
| Operating margin | — | 14.98% |
| Net margin | — | 5.47% |
| 52-week high | $4.90 | $247.49 |
| 52-week low | $2.72 | $101.00 |
| Distance from 52-week high | -20.20% | -28.57% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +24.37% |
| Average volume | 23.63K | 776.03K |
| Shares outstanding | 8.06M | 63.80M |
| Employees | — | 78,000 |
| Sector | Health Care | Health Care |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DaVita is about 357.8 times larger than Cryo-Cell International by market value ($11.28B vs $31.52M).
- DVA has outperformed CCEL by 46.2 percentage points over the past year.
About DaVita
DVA stock →DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States.
Health Care · Misc Health and Biotechnology Services · 78,000 employees
CCEL vs DVA FAQ
Which is bigger, Cryo-Cell International or DaVita?
DaVita (DVA) is larger, with a market capitalization of $11.28B compared with $31.52M for Cryo-Cell International (CCEL).
Which stock has performed better over the past year, CCEL or DVA?
DVA returned +34.91% over the past 12 months, compared with -11.34% for CCEL (price return, excluding dividends). Past performance does not predict future results.
Are Cryo-Cell International and DaVita in the same industry?
Yes. Both are classified in the Misc Health and Biotechnology Services industry within the Health Care sector.